Insilico, Tenacia Expand AI-Driven CNS Collaboration
Insilico Medicine and Tenacia Biotechnology have broadened their AI‑driven collaboration to create additional small‑molecule therapies for central nervous system disorders. Building on a March 2025 program that combined Insilico’s Pharma.AI platform with Tenacia’s proprietary data, the partners will use generative AI to design a second candidate with strong blood‑brain barrier permeability and move it to preclinical status. The expanded agreement adds up to $94.75 million in potential deal value, with near‑term and milestone payments to Insilico. Insilico also announced FDA clearance for a Parkinson’s disease trial in January 2026 and a co‑development deal for ISM8969 targeting NLRP3.
New AI Research Reshapes Neuroprotective Drug Discovery Funding
BCC Research’s new Pulse report, “AI Impact on Neuroprotective Agents,” outlines how artificial intelligence is reshaping the discovery, development, and delivery of neuroprotective therapies. The study projects a 4.5% CAGR for the North American market through 2030 and documents hundreds...
Bioventix SMA Adopted by Top IVD and Research Platforms
Positive update from Bioventix, confirming its position as a key player in the emerging Neurology & Alzheimer’s blood-testing market. “Amongst the RuO B-D pT217 assays being developed by the leading IVD companies (e.g. Roche, Siemens, Abbott, Beckman, Quidel-Ortho, Mindray etc.),...
Scalable Biotech Manufacturing Targets $14B Cell Therapy Market
Research forecasts the global cell‑therapy manufacturing market to exceed $7 billion in 2026 and reach $14 billion by 2035. The FDA has introduced new manufacturing flexibility to accelerate approval timelines for cell and gene therapies, addressing a capacity bottleneck that analysts expect...
The Future of Sex as a Biological Variable in Health Research
On Jan. 20, 2025 President Donald Trump signed an executive order that recognizes only two sexes and mandates federal agencies use the term “sex” instead of “gender.” The order abruptly removed the NIH Sex as a Biological Variable (SABV) policy webpages, unsettling...
Europe’s Pivotal Choice: Vaccination Is Health Security
Europe is positioning vaccination as a strategic asset, linking political will, science, and capital to secure health and economic resilience. The European Commission has pledged €225 million to fast‑track next‑generation flu vaccines, including the NOFLU consortium’s mRNA mucosal candidate. By integrating...
10 European Startups to Watch in 2026
A curated list of ten European biotech startups founded since 2021 showcases rapid progress toward clinical milestones and sizable financing. Companies such as Isomorphic Labs, Draig Therapeutics and Adcytherix are moving from platform development to first‑in‑human trials, backed by funding...
FDA Launches New AI-Powered System to Track Drug and Vaccine Side Effects
The FDA launched the AI‑powered Adverse Event Monitoring System (AEMS) on March 11, 2026, consolidating VAERS, FAERS and other databases into a single, real‑time platform. AI automates data entry and categorization, replacing quarterly updates with instant reporting. Early testing showed...
Study Finds MTFR1L Key to Slowing Heart Aging, Offers New Biohacking Target
Researchers at Sun Yat‑sen University's National Key Laboratory of Ophthalmology published a PNAS paper revealing that the protein MTFR1L maintains mitochondrial homeostasis in the heart and can slow age‑related cardiac decline. The findings open a molecular pathway for biohackers and...
Boston Scientific's EKOS System Cuts Pulmonary Embolism Mortality by 61% in HI-PEITHO Trial
Boston Scientific announced that its EKOS™ Endovascular System, combined with anticoagulation, lowered the 7‑day composite endpoint for intermediate‑risk pulmonary embolism to 4.0% versus 10.3% with anticoagulation alone, a 61% relative reduction. The findings, presented at ACC.26 and published in NEJM,...
Magnetic Nanorobots Offer Targeted Cancer Therapy, Researchers Claim
Scientists have demonstrated magnetic nanorobots smaller than blood cells that can be steered by external magnets to deliver chemotherapy directly to tumors. The technology aims to cut side effects and enable new hyperthermia treatments, signaling a potential shift in nanomedicine.
Analysts Forecast GLP-1 Biotech Stocks Could Triple by Year-End
Wall Street analysts project that GLP-1 focused biotech stocks could see their valuations triple before the end of 2026. The forecast highlights market leaders Novo Nordisk and Eli Lilly, while also flagging Viking Therapeutics as a high‑risk, high‑reward play.
Exposome Accelerates Brain Aging, Worsening Alzheimer’s Sleep Disturbances
Sleep disturbances and Alzheimer’s disease: a multiscale approach from exposome to neurobiology and precision medicine "a hypothetical integrative, stream-like model outlining how external and internal exposome factors accelerate brain aging, thereby exacerbating circadian dysregulation, orexin-mediated hyperexcitability, metabolic imbalance, and inflammaging." https://t.co/VJPZRqmM23
Johns Hopkins Releases First Clinical Guidance on Psychedelic Medicine
Johns Hopkins Medicine and Unbound Medicine have published the first ever clinical guidance on psychedelic medicine through the Johns Hopkins Psychiatry POC‑IT Guide. The guidance targets clinicians treating treatment‑resistant depression and PTSD, offering evidence‑based recommendations as psychedelic‑assisted therapies near FDA...
KAIST Unveils Graphene Oxide That Kills Bacteria Yet Remains Safe for Human Cells
A research team led by KAIST has identified how graphene oxide (GO) can selectively attack bacterial membranes while sparing mammalian cells, demonstrating rapid wound‑healing in mouse and pig models. The discovery could accelerate antimicrobial product development without relying on traditional...
AEON Biopharma Inc (AEON) Q4 2025 Earnings Call Transcript
Abeona Therapeutics reported 2025 results highlighting the commercial launch of ZevaSkin, its first autologous cell‑based gene therapy for recessive dystrophic epidermolysis bullosa. Total revenue reached $5.8 million, driven by $2.4 million product sales and a $1.5 billion gain from selling a priority‑review voucher,...
Actinium Pharmaceuticals Inc (ATNM) Q4 2025 Earnings Call Transcript
Actinium Pharmaceuticals reported adjusted 2025 revenue of $1.08 billion, a 14% increase year‑over‑year, driven by strong performance of its two core brands. NUPLAZID generated $692 million in adjusted net sales, up 15%, while DAYBUE posted $391 million, up 12%, aided by a 30%...
DeFi Development Corp (DFDV) Q4 2025 Earnings Call Transcript
Definium Therapeutics reported that its lead psychedelic candidate DT120 ODT is on track for three pivotal Phase III readouts in 2026. The EMERGE MDD study is fully enrolled with top‑line data expected in late Q2, while the VOYAGE GAD trial...
Unicycive Therapeutics Inc (UNCY) Q4 2025 Earnings Call Transcript
Unicycive Therapeutics reported a 40% revenue drop to $16.1 million for 2025, primarily from lost collaboration and contract manufacturing income, while license revenue modestly rose. R&D spending slipped slightly to $140.7 million, but SG&A surged $12.8 million as the company ramps up...
Guided Therapeutics Inc (GTHP) Q4 2025 Earnings Call Transcript
G1 Therapeutics announced FDA approval of COSELA, a first‑in‑class therapy that reduces chemotherapy‑induced myelosuppression in extensive‑stage small cell lung cancer. The company began commercial launch in early February 2021, reporting rising physician awareness and positive payer feedback. It also outlined...
Stress-Induced Plasminogen Activator Inhibitor-1 (PAI-1) as a Blood Biomarker and Brain Risk Factor for PTSD
Researchers identified plasminogen activator inhibitor‑1 (PAI‑1) as a stress‑responsive protein that rises in the dorsal hippocampus of mice and in the blood of humans with post‑traumatic stress disorder (PTSD). Using a restraint‑stress model, they showed that corticosterone triggers PAI‑1 up‑regulation...
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics reported Q4 2025 revenue of $41.9 million, bringing full‑year sales to $62.9 million driven by the rapid commercial uptake of its ROS1‑positive NSCLC therapy Iptrozi. The drug saw 432 new U.S. patients start treatment, with 216 in the quarter, a...
INmune Bio Inc (INMB) Q4 2025 Earnings Call Transcript
INmune Bio announced the first patient dosing in its phase‑2 XPro trial targeting neuroinflammation‑driven Alzheimer’s disease and outlined parallel phase‑2 studies in mild AD and MCI that leverage biomarker‑guided endpoints. The company also detailed a six‑week phase‑2 trial for treatment‑resistant...
USA Rare Earth Inc (USAR) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical reported 2025 revenue of $673 million, a 20% year‑over‑year increase that topped the upper end of guidance. The company announced a 10% workforce reduction to streamline costs and focus on near‑term value drivers. Pipeline highlights include resubmission of...
Lexeo Therapeutics Inc (LXEO) Q4 2025 Earnings Call Transcript
Exelixis reported record cabozantinib franchise revenue of $2.12 billion in the U.S. and $2.89 billion globally for 2025, a 17% year‑over‑year increase. Total Q4 2025 revenue reached $599 million, driven by $546.6 million from cabozantinib net product sales and $52.8 million in partner royalties. The...
Circuit-Targeted Modulation of Anxiety Symptoms in Individuals with Major Depression: A Randomized Head-to-Head TMS Trial
A randomized head‑to‑head trial compared two transcranial magnetic stimulation (TMS) targeting strategies in patients with major depressive disorder who also exhibit significant anxiety. Using circuit‑specific maps that differentiate anxiosomatic from dysphoric networks, the study found that the anxiosomatic‑targeted protocol produced...
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Transcript
RenovoRx reported Q4 2025 revenue of $266,000, bringing year‑to‑date sales to roughly $900,000 as it expands the RenovoCath platform across 14 approved cancer centers, up from five earlier in the year. The company ended the quarter with over $10 million in...
Correction: A Brain-Enriched circRNA Blood Biomarker Can Predict Response to SSRI Antidepressants
A correction was issued for the March 30 2026 paper on a brain‑enriched circRNA blood biomarker that predicts SSRI antidepressant response. The original manuscript mistakenly marked only one of three co‑corresponding authors, omitting the other two and their contact details. The update...
Kailera Plans IPO for Phase 3 Obesity Drug From Hengrui
Kailera Therapeutics, one of biotech’s best‑funded startups, announced plans to go public to finance the Phase 3 trial of its obesity drug co‑developed with China’s Hengrui. The IPO aims to raise capital that will position the company against heavyweight rivals such...
Li Ka-Shing’s CK Life Unit Eyes China Fast Track for Cancer Vaccine Pipeline
CK Life Sciences, the Li Ka‑shing‑backed unit, has created Sequencio Therapeutics in Hong Kong to fast‑track its cancer‑vaccine pipeline in mainland China using investigator‑initiated trials (IITs). The fast‑track channel can cut trial start‑up time from 18‑24 months to a few months,...
SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF
The SPIRIT‑HF trial, designed to test spironolactone in heart‑failure patients with preserved or mildly reduced ejection fraction, enrolled only 730 of the planned 1,564 participants and therefore lacked statistical power. Over two years, the composite of cardiovascular death or total...
Modulating RNA Folding Boosts Drug Efficacy More than Binding
Small molecules that alter RNA structure, rather than simply binding to it, have a greater impact on RNA function, highlighting the importance of targeting RNA folding in drug development. molecularbiology
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Rocket Pharmaceuticals received FDA approval on March 27 for KRESLADI, its first marketed product and the first gene therapy for a rare pediatric disorder. The clearance also awarded the company a Rare Pediatric Disease Priority Review Voucher, which can be...
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Allogene Therapeutics announced that its lead CAR‑T candidate cemacabtagene ansegedleucel (cema‑cel) stays on track in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation in large B‑cell lymphoma, enrolling over 60 sites globally. An interim futility analysis is slated for April 2026...
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Allogene Therapeutics announced that its lead CAR‑T candidate cema‑cel remains on schedule in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation of large B‑cell lymphoma, now enrolling at more than 60 sites worldwide. An interim futility analysis is set for...
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
Aardvark Therapeutics announced on March 23, 2026 that it is voluntarily pausing its Phase 3 HERO trial of ARD‑101 for Prader‑Willi syndrome and the ARD‑201 obesity program while it consults the FDA. The decision follows cardiac findings in healthy‑volunteer studies, where...
Deep Brain Stimulation Shows Early Promise for Treatment‑Resistant Depression
Researchers at UT Southwestern reported encouraging early results from a deep brain stimulation (DBS) trial targeting treatment‑resistant depression, a condition affecting roughly 30% of patients who fail conventional therapies. The study, part of the national TRANSCEND trial, suggests that electrical...
Tirzepatide Cuts Heart and Kidney Risk 16% vs Dulaglutide in Diabetes Study
A Cleveland Clinic secondary analysis of a 13,000‑patient trial shows tirzepatide lowers the combined risk of heart attack, stroke, heart failure, kidney failure and death by 16% versus dulaglutide. The findings, presented at the ACC meeting, give longevity‑focused biohackers new...
Natural SIRT1 Activators May Shield Early Alzheimer’s Microglia
Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis? 🗣️"We will describe how SIRT1 can represent a key molecular link and an appealing target to harness microglial neuroprotective potential as...
Scientists Intrigued by Microbe That That Makes Mice Swole
Researchers identified the gut bacterium Roseburia inulinivorans as a factor that boosts muscle strength in both humans and mice. In a cohort of 90 young adults and 33 seniors, individuals harboring the microbe exhibited up to 29% greater grip strength...
MRK's Sotatercept Shows Inverse Dose Response in 6
$TENX $TECX 🤔 $MRK sotatercept high dose *missed* stat sig on 6MWT in P2 (and it wasn’t particularly close). The low dose hit stat sig (barely) and was the dose taken to P3. What to make of a...
![[Articles] Aspirin versus Clopidogrel for Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: 10-Year Follow-Up of the HOST-EXAM Trial](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/f4390aa942546562889e73ef6cd4e624.webp)
[Articles] Aspirin versus Clopidogrel for Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: 10-Year Follow-Up of the HOST-EXAM Trial
Ten‑year extended follow‑up of the HOST‑EXAM trial compared clopidogrel 75 mg daily with aspirin 100 mg daily as chronic monotherapy after PCI. Among 5,438 patients, clopidogrel achieved a 25.4% incidence of the composite of death, MI, stroke, ACS readmission, or major bleeding...
![[Comment] Moving Beyond Aspirin After Percutaneous Coronary Intervention: 10-Year Results From the HOST-EXAM Trial](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/8acb026fc2949304b649926f35a196b8.webp)
[Comment] Moving Beyond Aspirin After Percutaneous Coronary Intervention: 10-Year Results From the HOST-EXAM Trial
The HOST-EXAM trial, with ten-year follow‑up, compared clopidogrel monotherapy to aspirin after percutaneous coronary intervention. Results showed clopidogrel achieved lower rates of major adverse cardiovascular events and major bleeding. The study enrolled over 5,000 patients from diverse centers, reinforcing the...
SGLT2 Inhibitors Help HFrEF Mice via Off‑Target Effects
SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice “The beneficial effects of SGLT2i treatment in gKO mice conclusively demonstrate that in a physiologically relevant preclinical model of HFrEF, SGLT2i can exert therapeutic benefits via off-target pharmacology.3...
Stopping Alzheimer’s Drugs Speeds Decline, Raises Death Risk
Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study https://t.co/YUcSc7w9HG
#ACC26: Merck Leans Toward Lower Winrevair Dose in Phase 3 Trial for Rare Form of Heart Failure
Merck announced that its experimental drug Winrevair will move into a pivotal Phase 3 trial for a rare form of heart failure, focusing on the lowest dose tested in Phase 2. The Phase 2 data showed a "pretty profound" efficacy signal at that...
Network Pharmacology Reveals Natural Products' Neuroprotective Power
Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review https://t.co/LGgQeHQHwF https://t.co/OiCYu2OxZq
Rapamycin Lessens Age‑related Motor Decline, Varies by Sex
Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice 👉"Our results are consistent with the idea that rapamycin’s beneficial effects are mediated, at least in part, by reducing oxidative stress and ER stress-mediated apoptosis... https://t.co/b8EZwrDTXP
Nektar's IL‑2 Variant Shows Strong Phase 2b Gains in Atopic Dermatitis and Alopecia Areata
Nektar Therapeutics presented Phase 2b data at the 2026 American Academy of Dermatology meeting showing statistically significant EASI improvements in 393 atopic dermatitis patients and a 28.2% mean SALT reduction in alopecia areata. The results position rezpegaldesleukin as the first IL‑2‑based...
GLP‑1 Drugs Now Help Psoriatic Arthritis Beyond Weight Loss
The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin https://t.co/kJej6osXTS